Health Care • Biotechnology: Pharmaceutical Preparations
$288.62 ▲ +3.14
(+1.10%)
MKT CAP: $8.06B • VOL: 508.6K
52W L $154 52W H $393
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$242
MEDIAN
$323
MEAN
$329
HIGH
$393
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE PRAX TAPE
PRAX // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $349.23 | $331.91 | 2025-02-14 | $262.64 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $363.66 | $340.57 | 2025-02-06 | $271.30 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $329.03 | $317.48 | 2025-01-29 | $277.08 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $294.39 | — | 2025-01-17 | $282.85 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $253.99 | $274.19 | 2025-01-09 | $256.87 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $343.46 | $300.16 | 2024-12-18 | $251.10 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $279.96 | $291.51 | 2024-12-04 | $268.42 | -4.3% | 48% | C |